> Novimmune entered into a bispecific antibody collaboration with Baxalta ($BXLT). Having inked the deal, Geneva, Switzerland-based Novimmune will use its kappa-lambda tech to generate antibodies capable of targeting two binding sites. "Our kappa-lambda antibodies … have promising development and safety characteristics such as a longer half-life, increased stability and a lower risk of provoking an unwanted reaction in patients," Novimmune research chief Nicolas Fischer said in a statement. Neither the indication nor the financial details were disclosed. Release
> Dr. John Hutchinson left Pfizer ($PFE) to become CMO at GlaxoSmithKline ($GSK) spinout Autifony Therapeutics. The appointment gives Autifony access to expertise Hutchinson accrued while working as CMO of Pfizer Neusentis, the Big Pharma's pain and sensory disorder R&D outpost in Cambridge, U.K. Hutchinson is replacing Dr. Peter Harris, who is retiring after almost three years in the post. Release (PDF)
> ADC Therapeutics raised $80 million (€71 million). The fundraising round saw founding investor Auven Therapeutics join with AstraZeneca ($AZN) and unidentified financiers to give the Lausanne, Switzerland-based antibody-drug conjugate specialist enough cash to see it through to 2018. ADC Therapeutics CEO Chris Martin sees the deal as another encouraging sign for the European biotech sector. "I'd say the quality of the investors is pretty solid now," Martin said. FierceBiotech
> NeuroSearch continued its slow slide toward the biotech graveyard. The Danish biotech, which has been in a tailspin since 2010 when it flip flopped on whether a trial had hit its endpoint, is still looking for buyers to take a pair of Phase I programs off its hands. And the legal fallout from the 2010 incident is still rumbling on. NeuroSearch was convicted of stock price manipulation last year but has appealed the ruling. A hearing is scheduled for later this month. Release
> Evotec (ETR:EVT) expanded its alliance with CHDI Foundation. The new deal runs to August 2018, over which time CHDI Foundation will bankroll the work of 55 full-time scientists at Evotec. Some of the work will take place at the facility in Toulouse, France that Evotec picked up from Sanofi ($SNY). Evotec plans to tap into technologies and capabilities it has gained through the addition of the site to its network to advance Huntington's disease research it is performing for CHDI Foundation. Release
> Pieris Pharmaceuticals ($PIRS) shifted its center of gravity from Freising, Germany, to Boston, MA. The drugmaker now lists Boston as its corporate headquarters and hub for R&D. Pieris initiated the shift shortly after pulling off a Nasdaq IPO. "The new Boston-based corporate and development headquarters is ideally located to help the company grow the human and financial resources necessary to develop, test, manufacture, commercialize and market our drug candidates," Pieris CEO Stephen Yoder said in a statement. Release